INO Inovio Pharmaceuticals Inc

$INO Another BULLISH close: 43,336 shares at $1.15, and at the high of the day. Have a nice weekend friends. Only 21 days until Christmas.

$INO 🎯 The Bottom Line for Your Buy DecisionThe fact that these talks are happening is backed up by the official FDA deadline calendar and management's formal statements to Wall Street banks. The only thing we don't see is how hard they are haggling behind closed doors over the fine print.Your logic remains the best compass: If the FDA intended to flat-out reject Inovio back in August, this September timeline for label negotiations would simply not exist.

$INO The Year 1 Surgery-Free Collapse • Precigen's Reality: In Precigen’s trial, 83% of patients (29 out of 35) received surgical clearing during the treatment window. While their official marketing states an "86% reduction in surgeries," the reality is that when you baseline the data to "Zero surgeries from Day 1," Precigen's true surgery-free rate drops to just 11.4%. • Inovio's Reality: Inovio did not allow any mid-dosing surgical cushions. Their reported 81.3% surgery-free rate is completely clean, meaning 26 out of 32 patients went from their very first dose to the end of Year 1 without a single surgical blade touching their throat.

$INO If they are awarded ~ $90M from VGXI (damages + all legal fees), that equals to 4 more qts of operations.

$INO I’ve added another $10K to my INOVIO position at $1.13. I’m very optimistic and believe we could see a strong move higher. I’m willing to risk around 30% on the downside with a stop-loss, but I genuinely think this could explode. The chain of catalysts around INOVIO is lining up, and there are a lot of positive signals building. I’m taking the risk because I believe the upside could be huge. 🚀

$INO Geneos news is indirectly positive for INOVIO. Geneos raised significant new capital in 2026 to advance its clinical programs, while continuing to use INOVIO’s DNA immunotherapy and CELLECTRA electroporation technology under license. The key benefit for INOVIO is that Geneos’ clinical success can create value for INOVIO through licensing/royalty payments, while INOVIO also retains an equity stake in Geneos. In short: More funding for Geneos → more clinical development → greater validation of INOVIO’s technology → potential future royalties and strategic value for INOVIO. This is not an immediate FDA catalyst for INOVIO, but it strengthens the long-term value of its technology platform and could become significantly more important if Geneos achieves strong Phase 2 results or signs a major pharmaceutical partnership.

$INO FDA won’t decline on Oct 30. Why? Because they started Label Negotiations in Sept. The FDA NEVER wastes time negotiating product labels if they plan a flat-out rejection. The "review issue" in the footnotes isn't a wall, it’s a legal bridge for a COMPROMISE: Accelerated Approval granted now (unmet medical need vs Precigen + unmatched 86% surgery-free data in Yr 2) + strict requirement to run the Phase 3 confirmatory trial concurrently. Label talks prove safety/efficacy boxes are checked.

$INO Don’t forget. Once approved in China, VGX-3100 will give women much comfort knowing: She won’t have to go through chemotherapy. She won’t have to go through radiation. She won’t have to go through surgery. And most importantly, she will be able to retain the ability to have a baby. This will be a game changer.

$INO FDA label negotiations are in the works. The next major step is FDA approval of INO-3107. The finish line is getting closer. 👏🏼

$INO Further analysis using AI... Based on historical biotech data and Inovio's specific regulatory milestones, the statistical probability that the FDA will grant accelerated approval on October 30, 2026, is estimated to be between 75% and 85%. In the biotechnology sector, a standard Phase 3 or late-stage BLA submission holds a baseline approval probability of roughly 65% to 70%. Inovio's specific regulatory timeline contains several strong indicators that push its odds well above the historical average: 🟢 Factors Driving the 75% – 85% Probability • Completion of All Prerequisite Audits: The FDA rarely moves toward an approval if manufacturing or facility issues remain outstanding. The official clearance of the late-cycle review meeting and the successful closure of all pre-licensure facility inspections mean there are no structural compliance roadblocks left on the table.

$INO Conclusion The Court should award to INO, jointly and severally against the Defendant 1) Compensatory damage in amount of $61.75M 2) Specific performance of Technology Transfer 3) A declaratory judgment that Inovio did not breach the contract 4) Inovio's Attorney's fees and costs 5) Post-judgment interest

$INO A Big Potential Issue With Precigen's RRP Treatment Is That It Is A Viral Vector Tech.....Outdated And Re Dosing Could Be A Big Issue....If You Do An AI Exploration Re Dosing Has Yet To Be Proven For Precigen's "Treatment"......Could This Be A Significant Issue For Precigen?.....Re Dosing With Antiquated Viral Vector Technology Has Historically Been An Issue

$INO 42 DAYS that’s all that’s left before FDA approval . We are getting very close now. Keep in mind FDA generally has a respond a week to ten days before the PDUFA date. At this stage, the FDA is generally working through the final pieces of the application clinical data, manufacturing/quality, inspections, safety, and the proposed labeling negotiations. If FDA is satisfied that the requirements for approval are met, it works with INOVIO to finalize the prescribing information before the approval decision.

$INO But the most important part is this: It's not about PGEN vs INO, it's getting as many treatment options to patients as possible. We as investors can invest in both if we so choose or try to pick a winner. But I think both will be winners and will co-exist in the market. The market is so big that it can easily support two big companies (not to mention other possible uses for their technologies). It's just that INO is currently so deeply undervalues compared to PGEN that it seems it's the must have investment at this point. And just by looking the trial data and technology it seems to me that INO has a edge which means that they may have a bit bigger piece of the pie if/when approved. But that remains to be seen, it can also go 50/50.

$INO With the multi-year VGXI litigation resolving favorably for Inovio, looking at the exact chronological alignment of these dates—the October 14 settlement next week followed by the October 30 PDUFA date—proves that Inovio's strategic position has evolved into a uniquely capitalized bull thesis: 1. Eliminating the "Grown-Up" Regulatory Risk Historically, when a small biotech company presents a single-arm, 32-patient trial for accelerated approval, the FDA worries about the feasibility of the post-marketing requirements. If the agency grants approval under the condition that the company runs a costly, multi-year confirmatory trial, an undercapitalized biotech running out of cash faces a real risk of corporate insolvency before completing it. The $61.75 million cash award plus legal fees fundamentally erases this regulatory anxiety. The FDA can confidently hand down a conditional approval knowing that Inovio's balance sheet is fully armed to fund the 100-patient confirmatory study

$INO Hmmm…the very first DNA plasmid medicine to be approved by the FDA is on the way. Think about that one for a minute.

$INO In reality, the FDA has already completed its manufacturing inspections for both the drug and the device components this autumn with no critical issues remaining.In short: The comment on Stocktwits/Reddit is factually incorrect. The FDA will either approve both together on October 30 via the expected compromise, or reject both. There is no scenario where the drug is approved but the "zapper" is left behind.

$INO INOVIO – Commercial Buildout Update INOVIO is actively building the infrastructure needed for a potential INO-3107 U.S. launch: • Expanding Medical Affairs / MSL teams • Building Commercial Operations & Field Sales • Working with Syneos Health for sales execution • Preparing market access, patient services and distribution • Specialty pharmacy, patient hub, logistics and marketing infrastructure already being organized PDUFA: October 30, 2026. This is clearly consistent with pre-launch commercial preparation, although it does not guarantee FDA approval.

$INO I’ve always looked at Precigen as a good benchmark for what the market could value INOVIO at. PGEN is now sitting around a $3B market cap, and they’re already showing what the RRP market can be worth. When INOVIO gets FDA approval for INO-3107 in 25 days or so, the market will have to revalue INO substantially. In my view, $8–$10 in the short term, with $20+ before year end. You cant have one company trading at $3B and anotherat $120M, offering similar or better product at the fraction, something would have to give. Approval and booom! 🚀🚀

$INO - 5 weeks to go from today until Inovio’s PDUFA. - 5th planet from the sun is Jupiter by the way. - 5% - Jupiter Topco acquired a good sized position in Inovio in the second quarter of 2026 - Jupiter Topco 4 holdings below got FDA approval (waiting for INO) so I guess their team of analyst know what they are doing - ASND 10th place among top institutional holdings and approval on February 27, 2026 - ARGX 3rd place at 3.95% approval for label expansion on May 8, 2026 - LNTH 3rd place at 7.95% approval on September 22, 2026 - MIRM 2nd place at 9.10% PDUFA on 9/26 but just got approval about an hour ago. - INO 2nd place at 5.00% PDUFA on 10/30 (Coming Soon)